Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.Qian Shi, Timothy Iveson, Roberto Labianca et al.|Journal of Clinical Oncology|2017Cited by 60
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).Timothy Iveson, James Paul, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2019Cited by 41
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.Alberto F. Sobrero, Qian Shi, Thierry André et al.|Journal of Clinical Oncology|2020Cited by 36
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.Claire Gallois, Julien Taı̈eb, Qian Shi et al.|Journal of Clinical Oncology|2022Cited by 8